 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...3940414243444546474849...858859» |
- | Prolia (denosumab) / Amgen
Preclinical, Journal: RANKL-mediated osteoclast formation is required for bone loss in a murine model of Staphylococcus aureus osteomyelitis. (Pubmed Central) - Aug 14, 2024
Mice were treated with vehicle or denosumab, a human monoclonal antibody that inhibits RANKL, both before and during a 14-day infection period...Lastly, there was a notable lack of osteoblasts near the infection site suggesting that the normal coupling of bone formation to bone resorption was disrupted by S. aureus infection. These results demonstrate that RANKL-mediated osteoclast formation is required for the bone loss that occurs in S. aureus infection and suggest that disruption of the coupling of bone formation to bone resorption may also contribute to bone loss in this condition.
- | Stivarga (regorafenib) / Bayer
Journal: Regorafenib-induced Myopathy. (Pubmed Central) - Aug 14, 2024
These results demonstrate that RANKL-mediated osteoclast formation is required for the bone loss that occurs in S. aureus infection and suggest that disruption of the coupling of bone formation to bone resorption may also contribute to bone loss in this condition. No abstract available
- | Journal: Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study. (Pubmed Central) - Aug 14, 2024
No abstract available Patients with bone metastases treated with immunotherapy within the Alpine Tumor Immunology Registry were compared based on whether they received an additional BTA such as denosumab or zoledronic acid...One hundred and ninety-seven patients with bone metastases and treatment with immunotherapy such as nivolumab (48
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Assessment of hearing dysfunction in patients with Graves' disease and thyroid eye disease without or with teprotumumab. (Pubmed Central) - Aug 14, 2024
These analyses indicate similar occurrence of hearing claims in patients with GD/TED alone as following teprotumumab treatment. Future analyses of incremental hearing risk from teprotumumab should utilize a priori study designs accounting for background hearing dysfunction in patients with GD/TED.
- | ivabradine / Generic mfg.
Trial completion date, Surgery: Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS) (clinicaltrials.gov) - Aug 14, 2024
P3, N=2500, Recruiting, Sponsor: Jagiellonian University
Future analyses of incremental hearing risk from teprotumumab should utilize a priori study designs accounting for background hearing dysfunction in patients with GD/TED. Trial completion date: Mar 2026 --> Jun 2026
- | Stivarga (regorafenib) / Bayer
Journal: Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma. (Pubmed Central) - Aug 13, 2024
Clinical data further confirm that high ILF3 or MRPL12 expression is associated with poor survival and targeted therapy efficacy in HCC. Conclusively, this findings suggest that ILF3 is a potential therapeutic target for overcoming resistance to TKIs, and lefamulin may be a novel combination therapy strategy for HCC treatment with sorafenib and regorafenib.
- | Ryzneuta (efbemalenograstim alpha) / Yifan Pharma
Journal: Ryzneuta for prevention of febrile neutropenia. (Pubmed Central) - Aug 13, 2024
Conclusively, this findings suggest that ILF3 is a potential therapeutic target for overcoming resistance to TKIs, and lefamulin may be a novel combination therapy strategy for HCC treatment with sorafenib and regorafenib. No abstract available
- || Tepezza (teprotumumab-trbw) / Roche, Amgen
Clinical, Journal: Teprotumumab for thyroid eye disease in patients with hypothyroid/euthyroid state: a multicenter case series. (Pubmed Central) - Aug 13, 2024
Teprotumumab reduces proptosis and inflammation in patients presenting with TED associated with hypothyroidism and euthyroidism. The results of this study highlight the potential for teprotumumab therapy in this subgroup and also provide a unique insight into the potential role of the IGF-1R in these patients.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Journal: CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer. (Pubmed Central) - Aug 13, 2024
The results of this study highlight the potential for teprotumumab therapy in this subgroup and also provide a unique insight into the potential role of the IGF-1R in these patients. In this study, it is
- | Prolia (denosumab) / Amgen
Retrospective data, Journal: A retrospective audit with subsequent cost and environmental analysis of a denosumab self-injection program. (Pubmed Central) - Aug 13, 2024
The cost analysis is based on our organization's 2022 charges. The SIP demonstrates that by focusing on care "closer to home", it is possible to maximize resources, improve the patient experience through reduced travel, and reduce the environmental impact of healthcare.
- || Nplate (romiplostim) / Amgen, Kyowa Kirin
Review, Journal: Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature. (Pubmed Central) - Aug 13, 2024
Recent treatment guidelines, including those from the National Comprehensive Cancer Network, now support consideration of romiplostim use in CIT. Data are expected from two ongoing phase 3 romiplostim CIT trials.
- | Venclexta (venetoclax) / Roche, AbbVie, Mavenclad (cladribine) / EMD Serono, navitoclax (ABT 263) / AbbVie
Enrollment change, Trial initiation date, Trial withdrawal: Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 13, 2024
P1, N=0, Withdrawn, Sponsor: Medical College of Wisconsin
Data are expected from two ongoing phase 3 romiplostim CIT trials. N=36 --> 0 | Initiation date: May 2024 --> Aug 2024 | Not yet recruiting --> Withdrawn
- ||| Rozlytrek (entrectinib) / Roche
Enrollment open: CRAFT: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (clinicaltrials.gov) - Aug 12, 2024
P2, N=52, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=36 --> 0 | Initiation date: May 2024 --> Aug 2024 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- |||| Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy: POLAR: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (clinicaltrials.gov) - Aug 12, 2024
P3, N=400, Recruiting, Sponsor: ETOP IBCSG Partners Foundation
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2024 --> Dec 2024
- | Stivarga (regorafenib) / Bayer
Journal: Liquidambaric acid inhibits the proliferation of hepatocellular carcinoma cells by targeting PPAR?-RXR? to down-regulate fatty acid metabolism. (Pubmed Central) - Aug 12, 2024
heterodimer, leading to the down-regulation of the ACSL4 gene and subsequently impacting the fatty acid metabolism of HCC cells, ultimately inhibiting HCC proliferation. Our research contributes to the identification of novel therapeutic agents and targets for the treatment of HCC.
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: "Teprotumumab for inactive thyroid eye disease? The jury is still out.". (Pubmed Central) - Aug 12, 2024
Our research contributes to the identification of novel therapeutic agents and targets for the treatment of HCC. No abstract available
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population. (Pubmed Central) - Aug 12, 2024
Treatment outcomes between the two types of CDK4/6i did not differ significantly, indicating the safety and efficacy of CDK4/6i for the Asian population. Ribociclib and palbociclib showed similar efficacy in PFS in the real-world setting.
- | veliparib (ABT-888) / AbbVie, motesanib (AMG 706) / Takeda
Biomarker, Journal, PARP Biomarker: ELF4 was a prognostic biomarker and related to immune infiltrates in glioma. (Pubmed Central) - Aug 12, 2024
Genomic analysis revealed that, in LGG, in the low ELF4 expression subgroup, IDH1 demonstrated a higher mutation rate, and TP53 and ATRX Chromatin Remodeler (ATRX) displayed the lower mutation rates, than the high ELF4 expression group. Our research suggests that ELF4 may contribute to the prognostic assessment of glioma and personalized medicine.
- | Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
Journal: Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians. (Pubmed Central) - Aug 12, 2024
Combination cyclophosphamide-rituximab may be the ideal way of studying minimal glucocorticoid use in severe AAV. Given its increasing uptake, incorporating avacopan into a potential trial design is important.
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Early and short-term use of proprotein convertase anti-subtilisin-kexin type 9 inhibitors on coronary plaque stability in acute coronary syndrome. (Pubmed Central) - Aug 12, 2024
Participants were randomly assigned to the PCSK9I group (evolocumab 420 mg for 3 months, n = 29) or the standard of care (SoC) group (n = 23)...Adage-Joto study, UMIN ID No. 26516.
- | cisplatin / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis. (Pubmed Central) - Aug 12, 2024
SBC is a chemosensitive subtype, with ypCR rate similar to urothelial bladder cancer following CGD neoadjuvant therapy. Whole transcriptome tissue analyses demonstrate increased expression of immune checkpoint and T-cell genes with therapeutic implications.
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Journal: Idiopathic Thrombocytopenic Purpura (ITP) Complicated by a Hemorrhagic Ovarian Cyst and Hemoperitoneum: A Case Report. (Pubmed Central) - Aug 12, 2024
The patient benefited from fluid resuscitation, blood transfusion, and corticosteroid therapy; then, the patient's condition improved. This case highlights the complications associated with managing ITP, emphasizing the importance of personalizing therapy regimens through regular monitoring to improve the balance of benefits and risk, resulting in a comprehensive treatment for chronic patients suffering from ITP.
- | Stivarga (regorafenib) / Bayer
Journal: Regorafenib Attenuates Osteoclasts Differentiation by Inhibiting the NF-?B, NFAT, ERK, and p38 Signaling Pathways. (Pubmed Central) - Aug 12, 2024
These results indicate that regorafenib exerts its protective effects against osteoclast-related osteolytic disease by inhibiting the RANKL-induced NF-?B, NFAT, ERK, and p38 signaling pathways. This study proves that regorafenib may serve as a potential therapeutic agent for osteoclast-related osteolytic diseases.
- || Opdivo (nivolumab) / BMS, Repatha (evolocumab) / Amgen, Astellas
Enrollment open: A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) (clinicaltrials.gov) - Aug 11, 2024
P2, N=29, Recruiting, Sponsor: M.D. Anderson Cancer Center
This study proves that regorafenib may serve as a potential therapeutic agent for osteoclast-related osteolytic diseases. Not yet recruiting --> Recruiting
- Tavneos (avacopan) / Amgen
17S03: Controversies in the Treatment of ANCA-Associated Vasculitis (Ballroom B; In Person) - Aug 11, 2024 - Abstract #ACRConvergence2024ACR_Convergence_431;
An ongoing controversy about the use of plasmapheresis persists despite the findings of the PEXIVAS study. The use of avacopan has opened an opportunity for glucocorticoid minimization and remaining indications for cyclophosphamide are important to discuss.Learning Objectives:
- Imdelltra (tarlatamab-dlle) / Amgen
Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance after Chemo-immunotherapy for ES-SCLC: DeLLphi-303 Phase 1b Study (20A) - Aug 11, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2764;
P1, P3
No new or unexpected toxicities were identified. This study supports further investigation of tarlatamab in combination with a PD-L1 inhibitor as 1LM in the ongoing phase 3 DeLLphi-305 randomized controlled study (NCT06211036).
- | Prolia (denosumab) / Amgen
Journal, Metastases: Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma. (Pubmed Central) - Aug 10, 2024
This study supports further investigation of tarlatamab in combination with a PD-L1 inhibitor as 1LM in the ongoing phase 3 DeLLphi-305 randomized controlled study (NCT06211036). In multivariable analysis, age younger than 48 years at PPGL diagnosis (HR, 0.558 [95
- | Lumakras (sotorasib) / Amgen
Journal, Metastases: Sotorasib (960 (Pubmed Central) - Aug 10, 2024
P1/2
In multivariable analysis, age younger than 48 years at PPGL diagnosis (HR, 0.558 [95 Patients treated with sotorasib 960
- ||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal, Adverse events: Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study. (Pubmed Central) - Aug 10, 2024
Abemaciclib showed higher risks of hepatotoxicity, gastrointestinal effects, interstitial lung disease, and thrombosis. These findings provide valuable insights for CDK4/6 inhibitor selection.
- || Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
P2 data, Journal: Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial. (Pubmed Central) - Aug 10, 2024
P2
Cytokine release syndrome (grade 1/2) was observed in 16% and neurotoxicity in 20% of patients. Blinatumomab demonstrated encouraging anti-tumour activity (the trial met its primary endpoint) and acceptable toxicity in patients with RT.
- || Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications. (Pubmed Central) - Aug 10, 2024
The presence of MRD has become an important predictive measure in Ph?+?ALL. Current studies evaluate the use of MRD in treatment decisions, especially in expanding therapeutic options for Ph?+?ALL, including tyrosine kinase inhibitors, targeted antibody therapies, chimeric antigen receptor cell therapy, and HCT.
- Prolia (denosumab) / Amgen
Utilization of Denosumab versus Bisphosphonate Therapy in the Pediatric Population (216_Level 2_South; In Person Only) - Aug 9, 2024 - Abstract #ACSCLINCON2024ACS_CLINCON_2079;
Additionally, patients taking denosumab had higher rates of hypercalcemia and severe bone pain. While invasive dental procedures should ideally be avoided during bisphosphonate treatment, our evidence suggests that bisphosphonates may be utilized safely in the pediatric population.
- Imlygic (talimogene laherparepvec) / Amgen
Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis (Quick-Shot) (216_Level 2_South; In Person Only) - Aug 9, 2024 - Abstract #ACSCLINCON2024ACS_CLINCON_997;
This work describes the experience using T-VEC in melanoma at a single institution. These data could help select patients who would benefit from intralesional therapy.
- |||| rocatinlimab (KHK4083) / Amgen
Trial primary completion date: ROCKET-ASCEND: A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (clinicaltrials.gov) - Aug 9, 2024
P3, N=2200, Recruiting, Sponsor: Amgen
These data could help select patients who would benefit from intralesional therapy. Trial primary completion date: Jun 2027 --> Jul 2025
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion date, Trial primary completion date: Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis (clinicaltrials.gov) - Aug 9, 2024
P2, N=8, Recruiting, Sponsor: Paul Szabolcs
Trial primary completion date: Jun 2027 --> Jul 2025 Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
- || Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: Recommendations for the optimal use of bone forming agents in osteoporosis. (Pubmed Central) - Aug 9, 2024
This sequential treatment approach ensures sustained protection and optimal resource utilization. In summary, the effective use of bone forming agents in osteoporosis requires a comprehensive strategy that includes accurate patient identification, consideration of cost-effectiveness, and implementation of appropriate sequential treatments, ultimately maximizing patient outcomes and healthcare efficiency.
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis. (Pubmed Central) - Aug 9, 2024
In summary, the effective use of bone forming agents in osteoporosis requires a comprehensive strategy that includes accurate patient identification, consideration of cost-effectiveness, and implementation of appropriate sequential treatments, ultimately maximizing patient outcomes and healthcare efficiency. No abstract available
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Author response to: OSIN-D-24-00849 Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis. (Pubmed Central) - Aug 9, 2024
No abstract available No abstract available
- | Tyvyt (sintilimab) / Eli Lilly, Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
New P2 trial, Circulating tumor DNA, Metastases: ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer (clinicaltrials.gov) - Aug 9, 2024
P2, N=68, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- ||| cirtuvivint (SM08502) / Biosplice Therap
Phase classification, Trial termination: A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 9, 2024
P1, N=30, Terminated, Sponsor: Biosplice Therapeutics, Inc.
No abstract available Phase classification: P1b --> P1 | Active, not recruiting --> Terminated; Study was terminated due business reasons by Sponsor.
- | Prolia (denosumab) / Amgen
Journal: Incidence and clinical course of femoral localized periosteal thickening and atypical femoral fracture over a 10-year period in patients with autoimmune inflammatory rheumatic disease. (Pubmed Central) - Aug 9, 2024
Phase classification: P1b --> P1 | Active, not recruiting --> Terminated; Study was terminated due business reasons by Sponsor. AFF occurred before BP discontinuation in 2 patients, 1
- | Humira (adalimumab) / AbbVie, Yuflyma (adalimumab-aaty) / Celltrion, Hikma
Journal: Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. (Pubmed Central) - Aug 9, 2024
AFF occurred before BP discontinuation in 2 patients, 1 The most commonly used drugs at inclusion were Humira
- || Prolia (denosumab) / Amgen, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Denosumab combined with chemotherapy followed by anlotinib in the treatment of multiple metastases of malignant peripheral nerve sheath tumor: a case report and literature review. (Pubmed Central) - Aug 9, 2024
In light of surgical limitations, a multimodal therapeutic approach combining chemotherapy, denosumab, and subsequent administration of anlotinib was pursued following collaborative consultation. This regimen yielded noteworthy clinical benefits, exemplifying a promising avenue in the management of challenging MPNST cases.
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Reversible cerebral vasoconstriction syndrome due to teprotumumab: two case reports. (Pubmed Central) - Aug 9, 2024
The temporal correlation between teprotumumab initiation and RCVS's symptom onset raises concern for the potential involvement of teprotumumab in triggering RCVS via disrupting cerebrovascular modulation. Further research is needed to investigate this proposed association.
- || astegolimab (RG 6149) / Amgen, Roche
Enrollment closed: A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects (clinicaltrials.gov) - Aug 9, 2024
P1, N=78, Active, not recruiting, Sponsor: Genentech, Inc.
Further research is needed to investigate this proposed association. Recruiting --> Active, not recruiting
- || Stivarga (regorafenib) / Bayer
Trial initiation date: Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial) (clinicaltrials.gov) - Aug 9, 2024
P2, N=104, Not yet recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
Recruiting --> Active, not recruiting Initiation date: Jun 2024 --> Sep 2024
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Retrospective data, Review, Journal: Association between bronchial asthma and TSLP gene polymorphism: a systematic review and meta-analysis. (Pubmed Central) - Aug 9, 2024
This meta-analysis shows that the SNP rs2289278 has a protective effect on the development of asthma; whereas rs3806933 has a risk of asthma. Additionally, this study adds genomic-based support to the recent FDA approval of tezepelumab, an anti-TSLP agent.
- | Simponi (golimumab) / J&J
Journal: Treatment of recurrent uveitis and ankylosing spondylitis with Golimumab: a case report, Letter to Editor. (Pubmed Central) - Aug 9, 2024
Till now, a case about treating refractory uveitis with Golimumab in AS patients was published. Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.
- | volagidemab (REMD-477) / Amgen, REMD Bio
Trial completion, Enrollment change: Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM (clinicaltrials.gov) - Aug 9, 2024
P1, N=4, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug. Suspended --> Completed | N=24 --> 4
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment change: Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (clinicaltrials.gov) - Aug 9, 2024
P2, N=39, Completed, Sponsor: Indiana University
Suspended --> Completed | N=24 --> 4 N=30 --> 39